Mental Disorder Or Mental Illness (e.g., Psychoses, Etc.) Affecting Patents (Class 514/17.5)
-
Patent number: 8012930Abstract: A therapeutic method for treating an individual diagnosed with PDD pervasive developmental disorder comprises determining the efficacy of digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level. A method for reducing the amount of methylphenidate (Ritalin) being taken by an individual with attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) by administering a therapeutic amount of digestive enzymes is also provided.Type: GrantFiled: March 11, 2008Date of Patent: September 6, 2011Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Publication number: 20110212890Abstract: Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in the blood and can have an excellent cancer metastasis inhibiting activity, an excellent cancer proliferation inhibiting activity, an excellent gonadotropin secretion inhibiting activity, an excellent sex hormone secretion inhibiting activity and the like by binding the metastin derivative to polyethylene glycol.Type: ApplicationFiled: July 29, 2009Publication date: September 1, 2011Applicant: Takeda Pharmaceutical Company LimitedInventor: Taiji Asami
-
Publication number: 20110212895Abstract: Constitutive activators of Rho GTPases are useful in treating learning an cognitive disorders.Type: ApplicationFiled: April 4, 2006Publication date: September 1, 2011Inventors: Giovanni Diana, Carla Fiorentini
-
Publication number: 20110201542Abstract: Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or transplanted tissues.Type: ApplicationFiled: April 27, 2011Publication date: August 18, 2011Applicant: The Board of Trustees of the University of IllinoisInventor: Herve Y. Sroussi
-
Publication number: 20110189161Abstract: The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions.Type: ApplicationFiled: June 22, 2009Publication date: August 4, 2011Inventors: Kenneth Blum, Roger L. Waite, B. William Downs, William J. Heaney
-
Publication number: 20110190212Abstract: Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and/or preventing stress-induced drug seeking behavior.Type: ApplicationFiled: July 10, 2009Publication date: August 4, 2011Applicant: UNIVERSITY OF KANSASInventors: Jane V. Aldrich, Nicolette C. Ross, Santosh Kulkarni
-
Publication number: 20110183909Abstract: The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders.Type: ApplicationFiled: October 2, 2009Publication date: July 28, 2011Applicant: UNIVERSITE PIERRE ET MARIE CURIEInventors: Jocelyne Caboche, Eleni Tzavara, Peter Vanhoutte, Bruno Giros
-
Publication number: 20110178021Abstract: The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder.Type: ApplicationFiled: May 26, 2009Publication date: July 21, 2011Applicant: INSTITUT PASTEURInventor: Catherine Rougeot
-
Publication number: 20110172158Abstract: The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.Type: ApplicationFiled: March 16, 2011Publication date: July 14, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, ROCKEFELLER UNIVERSITYInventors: David J. Gerber, Maria Karayiorgou, Tsuyoshi Miyakawa, Susumu Tonegawa
-
Publication number: 20110171128Abstract: The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as conjugates and pharmaceutical compositions comprising these polypeptides or conjugates. The present invention also relates to the use of these polypeptides for transporting a compound or drug across the blood-brain barrier of a mammal and in the treatment and diagnosis of neurological diseases.Type: ApplicationFiled: March 7, 2011Publication date: July 14, 2011Applicant: Angiochem Inc.Inventors: Richard BELIVEAU, Michel Demeule, Christian Che, Anthony Regina
-
Publication number: 20110171243Abstract: The present invention relates to the use of mimotopes in the treatment of ?-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated A?1-40/42, and N-terminally truncated forms A?pE3-40/42, A?3-40/42, A?11-40/42, A?pE11-40/42 and A?14-40/42 without interfering with physiological functions of APP signalling.Type: ApplicationFiled: June 12, 2009Publication date: July 14, 2011Applicant: AFFIRIS AGInventors: Markus Mandler, Radmila Santic, Harald Weninger, Edith Kopinits
-
Patent number: 7972633Abstract: Compositions for supporting healthy memory and optimizing mental energy and methods for improving, preventing, and treating mental disorders or deterioration. The compositions of the invention can be formulated as nutritional or dietary supplements.Type: GrantFiled: February 7, 2008Date of Patent: July 5, 2011Assignee: Applied Cognitive Sciences, LLCInventor: Kyl L. Smith
-
Publication number: 20110135652Abstract: There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.Type: ApplicationFiled: August 3, 2009Publication date: June 9, 2011Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITYInventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon
-
Publication number: 20110124571Abstract: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.Type: ApplicationFiled: April 7, 2009Publication date: May 26, 2011Applicant: INSTITUT PASTEURInventor: Catherine Rougeot
-
Publication number: 20110124572Abstract: The present invention provides a method for modulating the activity of Rac1, comprising modifying the phosphorylation state of Ser179 in syndecan-4 through influencing the interaction between syndecan-4 and the guanin nucleotide exchange factor of Rac1 (RacGEF) named Tiam1 in a GTP-dependent manner. In particular, methods are provided for enhancing the epithelial phenotype of a cell and for initiating the polarization of a cell by increasing the de-phosphorylation of said Ser179 of syndecan-4, and for enhancing the migratory phenotype of a cell and for initiating the neuronal differentiation of a cell by increasing the phosphorylation of said Ser179 of syndecan-4. Polypeptides for use in modulating the activity of the small GTPase Rac are also provided, as well as a method for identifying an agent capable of indirectly modulating the activity of the small GTPase Rac 1.Type: ApplicationFiled: July 24, 2009Publication date: May 26, 2011Inventors: László Szilák, Anikó Keller-Pintér, Tamás Letoha, József Tímár
-
Publication number: 20110117115Abstract: Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide, and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.Type: ApplicationFiled: December 9, 2004Publication date: May 19, 2011Inventors: Michal Eisenbach-Schwartz, Jonathan Kipnis
-
Publication number: 20110112033Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.Type: ApplicationFiled: October 13, 2010Publication date: May 12, 2011Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
-
Publication number: 20110110919Abstract: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.Type: ApplicationFiled: April 27, 2009Publication date: May 12, 2011Applicant: DSM IP ASSETS B.V.Inventors: Cinderella Christina Gerhardt, Luppo Edens
-
Publication number: 20110105389Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Hamid R. Hoveyda, Eric Marsault, Helmut Thomas, Graeme Fraser, Sylvie Beaubien, Axel Mathieu, Julien Beignet, Marc-André Bonin, Serge Phoenix, David Drutz, Mark Peterson, Sophie Beauchemin, Martin Brassard, Martin Vezina
-
Publication number: 20110104181Abstract: The present invention describes methods and compositions for modulating synaptogenesis and axon and/or dendritic growth. The methods include the use of agents that modulate a thrombospondin and/or an ?2? subunit of a calcium channel.Type: ApplicationFiled: October 15, 2010Publication date: May 5, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Cagla EROGLU, Ben A. BARRES
-
Publication number: 20110098213Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.Type: ApplicationFiled: November 4, 2005Publication date: April 28, 2011Applicant: Novo Nordisk A/SInventors: Ulrich Sensfuss, Leif Chritensen, Kilian Waldemar Conde Frieboes, Ingrid Pettersson
-
Publication number: 20110098225Abstract: The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to the use of said compounds for production of a medicament for treatment of conditions and diseases, wherein NCAM and/or FGFR play a prominent role.Type: ApplicationFiled: November 28, 2008Publication date: April 28, 2011Inventors: Vladimir Berezin, Elisabeth Bock, Søren Ebdrup, Boris Klementiev
-
Publication number: 20110086803Abstract: The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.Type: ApplicationFiled: October 30, 2007Publication date: April 14, 2011Inventors: Andre Leonardus De Roos, Luppo Edens, Rudolf Franciscus Van Beckhoven, Alexander Lucia Leonardus Duchateau, Joris Kloek
-
Publication number: 20110076347Abstract: This invention provides derivatives of dodecapeptide ISSIKEKYPSHS which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.Type: ApplicationFiled: May 14, 2009Publication date: March 31, 2011Inventors: Galila Agam, Orna Almog, Itzchak Levi, Yael Eskira, Yuly Bersudsky
-
Publication number: 20110053843Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.Type: ApplicationFiled: August 18, 2010Publication date: March 3, 2011Inventors: JOHN M. HALLENBECK, HIDEAKI WAKITA
-
Publication number: 20110052566Abstract: Inhibition of eIF-2? phosphorylation can be used to improve cognitive function and/or to treat dementia, including Alzheimer's Disease. In particular, this can be achieved by inhibiting the kinase activity of PKR in a non-toxic manner.Type: ApplicationFiled: June 30, 2010Publication date: March 3, 2011Applicant: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP., LTD.Inventors: Yaacov Rosenblum, Elad Stern, Yifat Segev
-
Patent number: 7897575Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.Type: GrantFiled: February 28, 2008Date of Patent: March 1, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John M. Hallenbeck, Hideaki Wakita
-
Publication number: 20110039785Abstract: The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder.Type: ApplicationFiled: December 19, 2008Publication date: February 17, 2011Applicant: Angiochem Inc.Inventors: Richard Béliveau, Michel Demeule, Christian Che, Anthony Regina
-
Publication number: 20100331258Abstract: The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.Type: ApplicationFiled: June 20, 2008Publication date: December 30, 2010Inventors: Patrick Joseph Gerardus Hendrikus Kamphuis, Martine Groenendijk, Anke Bongers
-
Publication number: 20100303785Abstract: The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics.Type: ApplicationFiled: January 10, 2008Publication date: December 2, 2010Inventors: Illana Gozes, Maya Maor, Saar Oz, David Dangoor, Inna Divinski
-
Publication number: 20100291196Abstract: The invention proposes the use of reduced glutathione encapsulated in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to improve symptoms in disease states related to diminished function of the methylation pathway such as autism, other neurodegenerative diseases and abnormalities of neurotransmitter levels in urine or blood. The invention also proposes combining liposomal encapsulated methylcobalamin, and/or liposomal encapsulated Insulin Growth Factor 1 (IGF-1) with liposomal reduced glutathione to accomplish such improvement.Type: ApplicationFiled: July 21, 2010Publication date: November 18, 2010Inventor: F. Timothy Guilford
-
Publication number: 20100286051Abstract: The present application is directed to a method of treating or preventing or ameliorating a neurological disorder associated with the disruption of a gene which encodes for an EphA6 polypeptide, the method comprising administering to a subject in need of such treatment whom may already have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of the therapeutic agent comprising a EphA6 polypeptide, or an agonist thereof, thereby effectively treating or preventing or ameliorating said disorder.Type: ApplicationFiled: October 14, 2009Publication date: November 11, 2010Inventors: Margaret L. Allen, Joel Edwards, Thomas Herbert Lanthorn, Katerina Savelleva
-
Publication number: 20100285045Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.Type: ApplicationFiled: December 14, 2006Publication date: November 11, 2010Applicant: Licentia LtdInventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen, Merja Voutilainen
-
Publication number: 20100256055Abstract: The present invention features a compound having the formula A-X—B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic selected from the group consisting of neurotensin, a neurotensin analog, or a neurotensin receptor agonist. The compounds of the invention can be used to treat any disease in which increased neurotensin activity is useful and can be used to induce hypothermia or analgesia.Type: ApplicationFiled: December 7, 2009Publication date: October 7, 2010Applicant: Angiochem Inc.Inventors: Jean-Paul CASTAIGNE, Michel DEMEULE, Christian CHE, Carine THIOT, Catherine GAGNON